ArticleInfection and drug resistance2025
Pharmacokinetic Profile of Isoniazid and Acetylator Status in Patients with Systemic Lupus Erythematosus: Implications for Tuberculosis Prevention Therapy in Indonesia.
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune inflammatory disease with a high risk of tuberculosis (TB) infection, especially in those living in TB-endemic areas. Isoniazid (INH), an anti-tuberculosis drug, is recommended as preventive therapy in TB susceptible groups, however, its use in SLE is still controversial. SLE patients are more likely to have compromised liver function which can influence the kinetic of INH. The aim of the study was to explore the pharmacokinetic profile of INH and acetylator status in SLE patients. Methods: This was a descriptive observational study with a purposive sampling technique, including adult female SLE at Dr. Hasan Sadikin Hospital Bandung, conducted in January - August 2023. Inclusion criteria were SLE patients in remission with no TB infection; whereas the exclusion criteria were INH allergy, liver or kidney disorders, pregnant or lactating patients, and malignancy. Pharmacokinetic data was collected from six blood collection time points (0, 1, 2, 3, 4, and 8 hours) after 10 days of daily INH 300 mg administration on an empty stomach. Results: In total, 20 female SLE patients were included. The C Conclusion: In terms of pharmacokinetic features, preventive isoniazid (INH) daily use of 300mg in SLE is sufficient to provide the prospect of protection from TB. These findings suggest that INH prophylaxis may be a viable strategy for TB prevention in SLE patients, warranting further investigation into long-term safety and efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.